• Home | Global Data CRO
  • Our Company
    • About Us
    • Executive Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Global Leaders
    • Working with MMS
    • Certifications
  • Services
    • Regulatory Affairs
      • Regulatory Affairs Services
      • Regulatory Strategy Consulting
      • Regulatory Affairs Management
      • Regulatory Operations
    • Data Management and Biostatistics
    • Regulatory and Medical Writing
    • Transparency Services
      • Transparency and Disclosure Services
      • REGISTRATION AND RESULTS DISCLOSURES
      • Data and Document Anonymization
      • LAY SUMMARIES
    • Quality and Compliance services
    • Drug Safety and Pharmacovigilance
    • Rare Disease
    • Quality Control Services
    • Project Advisory Services
    • Data Science
  • Technology
    • Datacise
    • Automatiqc
    • PVantage
    • Technology Implementation
    • SmartStart Document Templates
  • Functional Services (FSP)
  • Webinars
  • News and Media
  • MMS Blog
  • Careers
    • MMS Careers
    • Opportunities
    • MMS Experience
    • MMS Culture
    • Global Benefits
    • FAQ
  • Learning
  • Contact Us
MMS Holdings
PhUSE: Retrospective vs. Proactive Anonymization of Narratives

PhUSE: Retrospective vs. Proactive Anonymization of Narratives

by Avery Zimmerman | Mar 14, 2019 | Blog

Exerpt from whitepaper originally published by PhUSE on March 14, 2019 by project co-leads – Rashmi Dodia, MS, RAC and Gregory Campbell, BS Executive Summary Ever since policy 0070 was first introduced in 2016, there have been continuing concerns and challenges among...
Building a robust clinical data science process

Building a robust clinical data science process

by curtis@digitalliance.com | Jun 7, 2018 | Blog

During PhUSE US Connect 2018 – the clinical data science conference – in Raleigh, North Carolina, MMS data science experts presented a paper and corresponding poster, titled Big Data Paradox: Development of a Unique and Repeatable Analytical Process while Implementing...

Recent Posts

  • Award-Winning Data CRO Expands Executive Leadership to Support Company’s Next Stage of Growth
  • What is FDA’s Project Renewal? The Modernization of Decades Old Oncology Drug Labels
  • FDA Updates IND Expanded Access Guidance for Industry
  • What is Regulatory Information Management System (RIMS)?
  • Expanded Access to IND – Full Question and Answer in Draft Guidance

Tags

biostatistics Careers clinical research clinical study reports clinical trial disclosure clinical trials clinical trial transparency Compliance conference COVID-19 CRO data management data privacy data science decentralized clinical trials diversity and inclusion drug development eCOA & ePro EMA FDA Functional Service Provider (FSP) GXP auditing Health Analytics Collective innovation Lay summaries leadership medical writing MMS Academy NDA submission News Orphan Drug Designation Applications PDUFA VII pharmacovigilance PhUSE plain language summary Policy 0070 Praxis bioresearch quality and compliance quality control rare disease real world data regulatory affairs regulatory operations statistical programming transparency